◼ Archived
Business
Novartis secures new radioligand in $900M deal as competition strengthens
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
1 trends tracked about this subject — the full history, oldest to newest below.
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.